Fresenius Medical Care AG & Co. KGaA (FME.DE)
Fresenius Medical Care AG & Co. KGaA
Else-KrOener-Strasse 1
Bad Homburg 61352
Germany
49 6172 609 0
https://www.freseniusmedicalcare.com
Sector(s): Healthcare
Industry: Medical Care Facilities
Full-time employees: 119,845
Description
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Corporate governance
Fresenius Medical Care AG & Co. KGaA’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 1; Compensation: 9.
